What vaccine is the CDC recommending for 2017-2018 flu?
CDC | Morbidity and Mortality Weekly Report | Composition of the 2017–18 Influenza Vaccine
The Food and Drug Administration’s Vaccines and Related Biologic Products Advisory Committee (VRBPAC) has recommended that the 2017–18 influenza trivalent vaccine to be used in the United States contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like (B/Victoria lineage) virus.
It is recommended that quadrivalent vaccines, which have two influenza B viruses, contain the viruses recommended for the trivalent vaccines, as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus (2). This represents an update in the influenza A(H1N1) component compared with the composition of the 2016–17 influenza vaccines.
The recommended Northern Hemisphere 2017–18 vaccine viruses are the same as the vaccine viruses recommended for inclusion in the 2017 Southern Hemisphere influenza vaccines.
These vaccine recommendations were based on a number of factors, including global influenza virologic and epidemiologic surveillance, genetic and antigenic characterization, human serology studies, antiviral susceptibility, and the availability of candidate influenza viruses.
Ready to book your preferred 2017-2018 clinic dates? Read more about our corporate flu shot program and contact us today.